Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1193"
| Predicate | Value (sorted: none) |
|---|---|
| rdf:type | |
| rdf:type | |
| rdfs:label | |
| ?:Evidence_type | |
| ?:Evidence_enzyme_system | |
| dc:creator | |
| dc:date |
"09/21/2009 15:06:58"
|
| ?:content |
"CLINICAL PHARMACOLOGY
...
The major route of elimination of metronidazole and its metabolites is via the urine (60 to 80% of the dose), with fecal excretion accounting for 6 to 15% of the dose. The metabolites that appear in the urine result primarily from side chain oxidation [1-(Beta-hydroxyethyl)-2- hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-yl-acetic acid] and glucuronide conjugation, with unchanged metronidazole accounting for approximately 20% of the total. Renal clearance of metronidazole is approximately 10 mL/min/1.73 m2."
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ metronidazole_primary_total_clearance_mechanism_Renal_Excretion, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1078 }